To include your compound in the COVID-19 Resource Center, submit it here.

CSL Behring acquires Calimmune

The CSL Behring subsidiary of CSL Ltd. (ASX:CSL) said it will acquire gene therapy company Calimmune Inc. (Tucson, Ariz.), gaining two ex vivo autologous

Read the full 242 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE